World

Winners of Khalifa Award for Education to be announced in April

Jan 02, 2026

Abu Dhabi [UAE], January 2: The General Secretariat of the Khalifa Award for Education has announced the closure of nominations for the award's 19th cycle for 2025-2026, which was launched last July. The names of the winners are scheduled to be announced at the end of April.
This cycle includes 10 fields across 17 categories.
Hamid Al Houti, Secretary-General of the award, said the wide response from the education sector at the local, Arab and international levels reflects the award's distinguished standing.
According to the approved timeline, he explained, initial screening by specialised committees begins immediately after the close of nominations, followed by judging and evaluation of eligible submissions against the criteria set for each field and category.
Al Houti added that the process is conducted with full objectivity and transparency, in line with the award's vision of promoting a culture of excellence in education and academia.
This stage will be followed by field visits to a number of educational and community institutions shortlisted for the final round, to assess the tangible impact of the submitted projects and initiatives on the sector and the local community.
Source: Emirates News Agency

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026